Quantitative relationships between structure and pharmacokinetics of beta-adrenoceptor blocking agents in man

Peter H. Hinderling; Olga Schmidlin; Jochen K. Seydel

doi:10.1007/bf01061721

journal article Jun 01, 1984

Quantitative relationships between structure and pharmacokinetics of beta-adrenoceptor blocking agents in man

Peter H. Hinderling Olga Schmidlin Jochen K. Seydel

Journal of Pharmacokinetics and Biopharmaceutics Vol. 12 No. 3 pp. 263-287 · Springer Science and Business Media LLC

View at Publisher Save 10.1007/bf01061721

Topics

No keywords indexed for this article. Browse by subject →

References

71

[1]

J. K. Seydel and K. J. Schaper.Chemische Struktur und biolog. Aktivität von Wirkstoffen, Verlag Chemie, Weinheim, 1979, p. 73.

[2]

W. A. Craig and P. G. Welling. Protein binding of antimicrobials, clinical pharmacokinetics and therapeutic implications.Clin. Pharmacokin. 2:252–268 (1976). 10.2165/00003088-197702040-00002

[3]

W. J. Jusko and M. Gretch. Plasma and tissue protein binding of drugs in pharmacokinetics.Drug. Metab. Rev. 5:43–140 (1976). 10.3109/03602537608995839

[4]

J. K. Seydel. In J. C. Dowden (ed.),Quantitative Approaches in Drug Design, Elsevier, Amsterdam, 1983.

[5]

J. K. Seydel, D. Trettin, O. Wassermann, and M. Maliusz. Quantitative Struktur-Pharmacokinetik-Beziehungen am Beispiel von Sulfonamidobenzolen und Sulfanilamidopyridinen.J. Med. Chem. 23:607–613 (1980). 10.1021/jm00180a005

[6]

J. K. Seydel and K.-J. Schaper. In M. Rowland and G. T. Tucker (eds.),Pharmacology and Therapeutics, Vol. 15, Pergamon Press, Elmsford, N.Y., 1982.

[7]

A. J. Smith and G. T. Tucker. Kinetics and biotransformation of adrenergic inhibitors. In L. Szekeres (ed.),Adrenergic Activators and Inhibitors, Handbook Exp. Pharmacol, Springer-Verlag, Berlin, 1980, pp. 417–509.

[8]

N. D. S. Bax, M. S. Lennard, S. Al-Asady, C. S. Deacon, G. T. Tucker, and H. F. Woods. Inhibition of drug metabolism by beta-adrenoceptor antagonists.Drugs 25:(Suppl. 2): 121–126 (1983). 10.2165/00003495-198300252-00036

[9]

D. B. Jack. Is there a relationship between the physical properties and cardioselectivity of beta-adrenoceptor antagonists?Br. J. Clin. Pharmacol. 11:402–405 (1981). 10.1111/j.1365-2125.1981.tb01145.x

[10]

G. Neil-Dwyer, J. Artlett, J. McAinsh, and J. M. Cruishank. Beta-adrenoceptor blockers and the blood-brain barrier.Br. J. Clin. Pharmacol. 11:549–553 (1981). 10.1111/j.1365-2125.1981.tb01169.x

[11]

S. H. Unger and C. H. Chiong. Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high performance liquid chromatography and their correlation.J. Med. Chem. 24:262–270 (1981). 10.1021/jm00135a006

[12]

P. B. M. W. M. Timmermans, A. Brands, and D. A. von Zwieten. Lipophilicity and brain disposition of clonidine and structurally related imidazolidines.Naunyn-Schmiedebergs Arch. Pharmacol. 300:217–226 (1977). 10.1007/bf00500963

[13]

O. Fini, F. Brusa, and L. Chiesa. Bestimmung der Testzeit in der “Reversed-Phase” Hochdruckflüssigkeits-Chromatographie.J. Chromatogr. 210:326–330 (1981). 10.1016/s0021-9673(00)97843-9

[14]

A. C. Guyton.Testbook of Physiology, 4th ed., W. B. Saunders, Philadelphia, 1971, p. 427.

[15]

L. W. Schanker, P. A. Nafpliotis, and J. M. Johnson. Passage of organic bases into human red cells.J. Pharmacol. 133:325–331 (1961).

[16]

P. H. Hinderling. Kinetics of partitioning and binding of digoxin and analogs in the subcompartments of blood.J. Pharm. Sci., in press.

[17]

B. D. Davis. The binding of sulfonamide drugs by plasma proteins. A factor in determining the distribution of drugs in the body.J. Clin. Invest. 22:753–762 (1943). 10.1172/jci101448

[18]

M. Gibaldi and P. J. McNamara. Apparent volumes of distribution and drug binding to plasma proteins and tissues.Eur. J. Clin. Pharmacol. 13:373–378 (1978). 10.1007/bf00644611

[19]

S. Riegelman and P. Collier. The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time.J. Pharmacokin. Biopharm. 8:509–534 (1980). 10.1007/bf01059549

[20]

J. P. Kampman and J. Mølholm-Hansen. Glornerular filtration rate and creatinine clearance.Br. J. Clin. Pharmacol. 12:7–14 (1981). 10.1111/j.1365-2125.1981.tb01848.x

[21]

P. Hajdu and P. Damm. Physico-chemical and analytical studies of penbutolol.Arzneim. Forsch. 29:602–606 (1979).

[22]

M. Eckert, Hoffmann-La Roche Inc., Basle, Switzerland, personal communication.

[23]

D. A. Stopher, Pfizer Ltd., Sandwich, England, personal communication.

[24]

D. C. Hicks. The buccal absorption of some beta-adrenoceptor blocking drugs.Br. J. Pharmacol. 47:680P-681P (1973).

[25]

N. O. Bodin, K. O. Borg, R. Johannson, H. Obianwu, and R. Svenson. Absorption, distribution and excretion of alprenolol in man, dog and rat.Acta Pharmacol. Toxicol. 35:261–269 (197). 10.1111/j.1600-0773.1974.tb00745.x

[26]

C. P. Dawes, M. J. Kendall, and V. A. John. Comparison of plasma and saliva levels of metoprolol and oxprenolol.Br. J. Pharmacol. 5:217–221 (1978). 10.1111/j.1365-2125.1978.tb01627.x

[27]

R. Tempelton, May Baker Ltd., Dagenham, England, personal communication.

[28]

P. Vermeij. Kinetische aspecten van einige beta-blockkeerbers, Ph.D. thesis, Amsterdam, 1976.

[29]

C.-G. Regårdh, K. O. Borg, R. Johansson, G. Johnsson, and L. Palmer. Pharmacokinetic studies on the selective beta,-receptor antagonist metoprolol in man.J. Pharmacokin. Biopharm. 2:347–364 (1974). 10.1007/bf01061407

[30]

M. Lemaire and J. P. Tillement. The binding characteristics of some adrenergic betareceptor antagonists to human serum proteins.Biochem. Pharmacol. 31:359–362 (1982). 10.1016/0006-2952(82)90183-6

[31]

H. K. Adam, Imperial Chemical Industries Ltd., Macclesfield, England, personal communication.

[32]

U. N. Pfluger, Squibb Inc., Zürich, Switzerland, personal communication.

[33]

E. R. Garrett and K. Schnelle. Separation and spectrofluorometric assay of the betaadrenergic blocker sotalol from blood and urine.J. Pharm. Sci. 60:833–839 (1971). 10.1002/jps.2600600607

[34]

D. Hellenbrecht, B. Lemmer, G. Wiethold, and H. Grobecker. Measurement of hydrophobicity, surface activity, local anesthesia and myocardial conduction velocity as quantitative parameters of the non-specific membrane affinity of nine beta-adrenergic blocking agents.Naunyn-Schmiedebergs Arch. Pharmacol. 277:211–226 (1973). 10.1007/bf00501161

[35]

T. J. Coombs and C. J. Coulson, May Baker Ltd., Dagenham, England, personal communication.

[36]

W. Riess, S. Brechbühler, and W. Theobald. The pharmacokinetic characteristics of beta-receptor antagonists in man-similarities and differences of clinical relevance.Aust. N. Z. J. Med. 6(Suppl.3):4–13 (1976). 10.1111/j.1445-5994.1976.tb03327.x

[37]

T. J. Coombs, C. J. Coulsen, and V. J. Smith. Blood plasma binding of acebutolol and diacetolol in man.Br. J. Clin. Pharmacol. 9:395–397 (1980). 10.1111/j.1365-2125.1980.tb01067.x

[38]

C. Appelgreen, K. O. Borg, R. Elofsson, and K. A. Johannson. Binding of adrenergic beta-receptor-antagonists to human serum albumin.Acta Pharm. Suec. 11:325–332 (1974).

[39]

P. B. Woods and H. L. Robinson. An investigation of the comparative liposolubilities of beta-adrenoceptor blocking agents. JPharm. Pharmacol. 33:172–173 (1981). 10.1111/j.2042-7158.1981.tb13743.x

[40]

J. K. Faulkner, D. A. Stopher, R. Waiden, W. Singleton, and S. H. Taylor. Pharmacokinetic and pharmacological studies with tolamolol in man.Br. J. Clin. Pharmacol. 2:423–428 (1975). 10.1111/j.1365-2125.1975.tb00551.x

[41]

F. M. Belpaire, M. G. Bogaert, and M. Rosseneu. Binding of beta-adrenoceptor blocking drugs to human serum albumin, to alpha1-glycoprotein and to human serum.Eur. J. Clin. Pharmacol. 22:253–256 (1982). 10.1007/bf00545224

[42]

P. J. Meffin, R. A. Winkle, F. A. Peters, and D. C. Harrison. Acebutolol disposition after intravenous administration.Clin. Pharmacol. Ther. 22:557–567 (1977). 10.1002/cpt1977225part1557

[43]

J. A. Henry and S. N. Mitchell. Effect ofpH on human plasma protein binding of a series of beta-adrenoceptor antagonists.Br. J. Clin. Pharmacol. 11:119P-120P (1980).

[44]

J. Dreyfuss, J. Brannick, R. A. Yukovich, J. M. Shaw, and D. A. Willard. Metabolic studies in patients with nadolol: oral and intravenous administration.J. Clin. Pharmacol. 17:300–307 (1977). 10.1002/j.1552-4604.1977.tb04609.x

[45]

M. Antilla, M. Arstila, M. Pfeffer, R. Tikkanen, V. Vallinkoski, and H. Sundquist. Human pharmacokinetics of sotalol.Acta Pharmacol. Toxicol. 39:118–128 (1976). 10.1111/j.1600-0773.1976.tb03162.x

[46]

L. B. Jellet and D. G. Shand. Uptake of propranolol by washed human red cells.Pharmacologist 15:215 (1973).

[47]

G. Alvan, K. Piafsky, M. Lind, and C. von Bahr. Effect of pentobarbital on the disposition of alprenolol.Clin. Pharmacool Ther. 22:316–321 (1977). 10.1002/cpt1977223316

[48]

J. P. Dubois, CIBA-GEIGY Ltd., Basle, Switzerland, personal communication.

[49]

M. Lemaire, Ph.D. thesis, Universite de Paris de l'Est, 1982.

[50]

P. R. Reeves, D. E. Case, H. T. Jepson, D. J. McCormick, J. T. Nickolls, R. H. Felix, P. J. Holt, K. J. Zacharias, and R. W. Fluke. Practolol metabolism II. Metabolism in human subjects.J. Pharmacol. Exp. Ther. 205:489–498 (1978).

Showing 50 of 71 references

Metrics

72

Citations

71

References

Details

Published: Jun 01, 1984
Vol/Issue: 12(3)
Pages: 263-287
License: View

Authors

Cite This Article

Peter H. Hinderling, Olga Schmidlin, Jochen K. Seydel (1984). Quantitative relationships between structure and pharmacokinetics of beta-adrenoceptor blocking agents in man. Journal of Pharmacokinetics and Biopharmaceutics, 12(3), 263-287. https://doi.org/10.1007/bf01061721

Quantitative relationships between structure and pharmacokinetics of beta-adrenoceptor blocking agents in man

You May Also Like